Intellia Therapeutics Inc (NASDAQ:NTLA)
| 34.00 Delayed Data As of Sep 20 |  -0.38 / -1.11%Today’s Change | 32.44 Today|||52-Week Range 65.12 | -2.55% Year-to-Date |
Latest NTLA News | Press Releases
| 1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know Sep 19 / MotleyFool.com - Paid Partner Content | Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double Sep 10 / MotleyFool.com - Paid Partner Content |
| 2 Top Trends to Invest $500 In Right Now Sep 18 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 34.37 |
| Today’s open | 34.68 |
| Day’s range | 33.88 - 34.94 |
| Volume | 801,899 |
| Average volume (3 months) | 880,299 |
| Market cap | $3.2B |
Data as of 3:59pm ET, 09/20/2023
Growth & Valuation
| Earnings growth (last year) | -63.03% |
| Earnings growth (this year) | +13.84% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +57.69% |
| P/E ratio | NM |
| Price/Sales | 51.53 |
| Price/Book | 2.53 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| DNLIDenali Therapeutics ... | +0.13 | +0.59% |
| BPMCBlueprint Medicines ... | -0.76 | -1.48% |
| ---- | ||
| ARWRArrowhead Pharmaceut... | -0.22 | -0.81% |
Data as of 4:00pm ET, 09/20/2023
Financials
| Next reporting date | November 2, 2023 |
| EPS forecast (this quarter) | -$1.38 |
| Annual revenue (last year) | $52.1M |
| Annual profit (last year) | -$474.2M |
| Net profit margin | -909.78% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
